tiprankstipranks
Advertisement

FTCS - ETF AI Analysis

Compare

Top Page

FTCS

First Trust Capital Strength ETF (FTCS)

Rating:74Outperform
Price Target:
FTCS, the First Trust Capital Strength ETF, appears to hold generally solid, high-quality companies, with strong contributors like Merck and Vertex Pharmaceuticals benefiting from robust financial performance, attractive or reasonable valuations, and promising growth pipelines. Several other holdings such as Amgen, ResMed, and Garmin also support the fund’s quality through strong earnings and strategic growth, though their high valuations and some bearish technical signals, along with weaker names like 3M facing leverage and profitability concerns, slightly weigh on the overall rating. The main risk factor is that many holdings show valuation and technical caution, which could increase volatility if market sentiment turns.
Positive Factors
Strong Overall Performance
The ETF has delivered steady gains so far this year, supported by positive recent returns over the last few months.
Broad Sector Diversification
Holdings spread across financials, industrials, consumer defensive, health care, consumer cyclical, technology, energy, and materials help reduce the impact of weakness in any single sector.
Multiple Strong Top Holdings
Several of the largest positions, including EOG Resources, Ross Stores, Coca-Cola, and T. Rowe Price, have shown strong year-to-date performance, providing a solid foundation for the fund.
Negative Factors
Higher Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which means more of the returns are used to cover fees.
Single-Country Concentration
With all of its exposure in U.S. companies, the ETF offers no geographic diversification and is fully tied to the U.S. market’s fortunes.
Underperforming Top Holding
One of the top positions, Expand Energy, has shown weak year-to-date performance, which can drag on the fund if the stock continues to lag.

FTCS vs. SPDR S&P 500 ETF (SPY)

FTCS Summary

FTCS, the First Trust Capital Strength ETF, follows the NASDAQ Capital Strength Index and invests in large U.S. companies with strong finances and steady earnings. It spreads money across many sectors like financials, industrials, health care, and consumer goods, and holds well-known names such as Coca-Cola and 3M. Someone might invest in FTCS to seek long-term growth from solid, established businesses while still getting diversification across the economy. A key risk is that, even with strong companies, the ETF’s value can still go up and down with the overall stock market.
How much will it cost me?The First Trust Capital Strength ETF (FTCS) has an expense ratio of 0.52%, which means you’ll pay $5.20 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed, focusing on selecting financially strong companies rather than tracking a broad index. Active management typically involves more research and decision-making, which increases costs.
What would affect this ETF?The First Trust Capital Strength ETF (FTCS) could benefit from stable economic growth and increased demand for financially strong companies, especially in sectors like Industrials and Technology, which are key components of the fund. However, rising interest rates or economic uncertainty could negatively impact sectors such as Financials and Consumer Cyclical, while regulatory changes or geopolitical tensions might affect its U.S.-focused holdings. Investors should monitor these factors to assess potential risks and opportunities.

FTCS Top 10 Holdings

FTCS leans heavily into U.S. large caps with a defensive tilt, and its story right now is being written by steady health care and industrial names. Merck and Amgen are rising and helping to anchor performance, while Garmin’s solid run adds a tech-flavored boost. On the flip side, Copart has been lagging and ResMed looks a bit tired, acting as mild brakes on the fund. With broad sector exposure but no single mega-cap dominating, the ETF feels more like a balanced lineup of sturdy players than a high-octane, theme-driven bet.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Airbnb2.48%$197.64M$113.43B45.12%
71
Outperform
Resmed2.31%$183.95M$34.67B-12.45%
76
Outperform
Copart2.29%$181.99M$30.54B-32.41%
71
Outperform
Amgen2.26%$179.80M$233.78B50.30%
77
Outperform
CME Group2.23%$177.64M$102.77B7.24%
74
Outperform
Merck & Company2.23%$177.22M$366.00B76.36%
80
Outperform
Garmin2.19%$174.06M$55.00B17.93%
74
Outperform
Automatic Data Processing2.15%$171.53M$114.21B-5.45%
70
Outperform
Vertex Pharmaceuticals2.13%$169.88M$137.30B38.53%
78
Outperform
Expand Energy2.13%$169.64M$22.72B1.42%
71
Outperform

FTCS Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
98.62
Positive
100DMA
95.88
Positive
200DMA
94.97
Positive
Market Momentum
MACD
0.53
Positive
RSI
53.08
Neutral
STOCH
12.60
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FTCS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 100.93, equal to the 50-day MA of 98.62, and equal to the 200-day MA of 94.97, indicating a neutral trend. The MACD of 0.53 indicates Positive momentum. The RSI at 53.08 is Neutral, neither overbought nor oversold. The STOCH value of 12.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FTCS.

FTCS Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$7.87B0.53%
74
Outperform
$9.99B0.39%
72
Outperform
$8.79B0.12%
73
Outperform
$8.71B0.06%
73
Outperform
$8.58B0.18%
73
Outperform
$8.42B0.31%
69
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FTCS
First Trust Capital Strength ETF
100.59
8.48
9.21%
RWL
Invesco S&P 500 Revenue ETF
JQUA
JPMorgan U.S. Quality Factor ETF
VONE
Vanguard Russell 1000 ETF
FELC
Fidelity Enhanced Large Cap Core ETF
TCAF
T. Rowe Price Capital Appreciation Equity ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement